![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by RobertDavid on May 19, 2006, at 19:46:42
The following are a two paragraphs from an article in the Pychiatric Times. It mentions comments from Wayne Goodman, the FDA advisory committe chairperson about the development of a new drug that would be a possible competitor to EMSAM. Does anyone have any info on this drug, heard about it? Perhaps their will be a new option to EMSAM coming out. I wonder if it's an existing MAOI or ????
While the members of the advisory committee are mostly academics, 8 of the 11 members had relationships with drug companies whose products could have been affected by decisions the advisory committee made that day. Before the meeting started, Karen M. Templeton-Somers, PhD, acting executive secretary, read off a list of those members and their relationships. She noted that the advisory committee's chairperson, Wayne Goodman, MD, works for 2 employers (the University of Florida College of Medicine and the McKnight Brain Institute at the University of Florida) that have 4 separate contracts—2 with firms funded at less than $100,000 per year and 2 others with separate drug firms funded at between $100,001 and $300,000 per year.
Goodman pointed out that those relationships pertained to contracts held by other investigators in his department with a company developing a drug that would be a competitor to selegiline (Emsam), the first transdermal patch medication used for treating major depression. The committee voted to recommend Emsam's approval on the second day of that October meeting, and the FDA approved the drug on February 28, 2006. Emsam was developed by Somerset Pharmaceuticals,Inc. In December 2004, Bristol-Myers Squibb and Somerset entered into an agreement that provides Bristol-Myers Squibb with distribution rights to market Emsam.
Posted by Phillipa on May 19, 2006, at 22:49:48
In reply to EMSAM- is there a new competitor in the works?, posted by RobertDavid on May 19, 2006, at 19:46:42
Rob that would be wonderful a competitor. E-mail me and let me know how you're doing Love Jan
Posted by SLS on May 20, 2006, at 8:14:19
In reply to EMSAM- is there a new competitor in the works?, posted by RobertDavid on May 19, 2006, at 19:46:42
It might be rasagiline.
- Scott
Posted by Last Chance on May 20, 2006, at 12:57:27
In reply to Re: EMSAM- is there a new competitor in the works, posted by SLS on May 20, 2006, at 8:14:19
Rasagiline in Europe, online, priced at $249.95 for 28 1mg tablets. A patch? - maybe - but I wonder what the price tag on that baby would be. Richard
Posted by lymom3 on May 21, 2006, at 21:19:15
In reply to Re: EMSAM- is there a new competitor in the works, posted by Last Chance on May 20, 2006, at 12:57:27
My Emsam that I just got filled at Walgreens would have been $478.00 without insurance...it's nuts
Posted by aabag on May 22, 2006, at 10:57:12
In reply to Re: EMSAM- is there a new competitor in the works » Last Chance, posted by lymom3 on May 21, 2006, at 21:19:15
I guess its nuts, but when consider the multitude of tests you must go through to ultimately get a drug approved, that costs there too are nuts. In an of itself, each drug, with the efficacy trials, safety trials, animal trials, research staff salaries and materials, carcincinogenicity tests, drug-drug interaction tests, filing costs...its amazing that all but the largest companies can get new products to market.
For example, the concept of GABA-A receptor subtype specific anxiolytics has been around since 1980 or thereabouts, yet we have yet to have a single compound on the market to take advantage of this. Ocinaplon almost made it, but was shut down due to liver issues. I now see other companies cropping up (Neurion) around the same concept, and Dov Pharmaceutical, if it survives the multi-million dollar loss w/ the recent FDA "dis"-approval, will also continue working in this area. If I had the sales leadership, I'm half inclined to get some investors together to work on this area, because non-sedative, non-dependency producing anxiolytics are needed and their would be a massive market for them.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.